

In the Claims:

Please amend claims

36 - 51 , as detailed below.

36.(Currently amended) A ~~method~~ process for the ~~measurement of the ability of a surface to bind or internalize a material, consisting~~ evaluation of biological factor or biological ligand binding and/or internalization using non-radioisotopic immunologically recognizable hapten-conjugated (labeled) factors or ligands, consisting essentially of:

- A. ~~Application of a material~~ Applying said factor or ligand possessing a an immunologically recognizable hapten group (hereafter referred to as labeled ligand-material) to a surface; in the presence or absence of the same ~~material factor or ligand~~ which does not possess the immunologically recognizable group (hereafter referred to as unlabeled material ligand).
- B. ~~Removal of~~ Removing non-surface associated labeled and unlabeled ~~material ligand~~ from the surface environment.
- C. ~~Removal of~~ Solubilizing surface-associated labeled and unlabeled ligand material; with or without disruption of the surface.
- D. Optional: separation of ~~separating~~ removed previously surface-associated labeled and unlabeled ~~material ligand~~ ; with or without ~~concomitant separation of~~ concomitantly separating known amounts of labeled material ligand.

- E. Blotting of non-separated (C.) or separated (D.) ~~removed~~ solubilized previously surface associated labeled and unlabeled ~~material~~ ligand onto a matrix; with or without concomitant blotting of known amounts of labeled ~~material~~ ligand.
- F. ~~Detection of~~ Detecting all blot matrix-associated, previously surface associated, labeled ~~material~~ ligand, using a specific label recognizing entity; followed by ~~specific detection of~~ specifically detecting that entity.
- G. Optional: ~~Determination of~~ Determining the amount of the blot matrix-associated previously surface-associated labeled ~~material~~ ligand, by ~~comparison of~~ comparing its respective signals to those the signals obtained from blot matrix-associated known amounts of labeled ~~material~~ ligand.

37. (currently amended) The ~~claim of~~ process as claimed in claim 36, ~~where the~~ wherein ~~said surface is~~ consists of comprised of, but is not limited to, biological cells.
38. (currently amended). The ~~claim of~~ process as claimed in claim 36, where the immunologically recognizable group (haptens) ~~consists of~~ is: comprised of, but is not limited to, fluorescein, biotin, rhodamine, digoxigenin, or any other antibody-recognizable entity.
- 39 (currently amended). The ~~claim of~~ process as claimed in claim 36, ~~where the~~ ~~material consists of~~ wherein said biological ligand is comprised of, but is not limited to, transferrin, concanavalin A, avidin, annexin V, insulin, or any other protein, carbohydrate, nucleic acid, or any other substance or material which can possess said immunologically recognizable group.

40. (currently amended) The ~~claim of~~ process as claimed in claim 36, where the
~~separation method is~~ wherein previously surface-associated labeled and unlabeled
ligand can be separated by a method comprised of, but not limited to: electrophoresis,
wherein such electrophoresis methodology consists of , but is not limited to sodium
dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE), or other form of de-
naturing or non-denaturing electrophoresis.
41. (currently amended) The ~~claim of~~ process as claimed in claim 36, where wherein
~~said the~~ blotting method is comprised consisting of, but is not limited to, dot blotting,
slot blotting, or Western blotting.
42. (currently amended) The ~~claim of~~ process as claimed in claim 36, where the-wherein
said blotting matrix is comprised of consists of, but is not limited to, nitrocellulose,
or any other suitable blotting matrix.
43. (currently amended) The ~~claim of~~ process as claimed in claim 36, where the detection
wherein the detecting of blot matrix-associated labeled ligand is comprised of labeled
~~material consists of~~, but is not limited to, applying to the matrix ~~application of~~ an
enzyme-conjugated or otherwise traceable anti-label antibody, followed by
colorimetric, luminescent or other based detection of the antibody's enzyme or
traceable entity.
44. (currently amended) The ~~claim of~~ process as claimed in claim 36, where the detection
detecting of blot matrix-associated labeled material consists ligand is comprised of,
but is not limited to, application of an enzyme-conjugated or otherwise traceable
avidin or streptavidin, followed by colorimetric, luminescent or other based detection
of the avidin's or streptavidin's enzyme or traceable entity.

45. (currently amended) The ~~claim of~~ process as claimed in claim 36, where the ~~detection~~ wherein the detecting of blot matrix-associated labeled material is comprised of ~~consists of~~, but is not limited to, applying to the matrix ~~application of~~ any sequence of antibodies; wherein the labeled ligand is detected, such as: ~~application of~~ applying an anti-label antibody, followed by ~~application of~~ applying an antibody to the anti-label antibody, followed by ~~application of~~ applying an antibody to the antibody to the anti-label antibody, etc.; with the final antibody possessing a conjugated enzyme or traceable group entity. Wherein the amount of final antibody is determined by colorimetric, luminescent or other based ~~detection~~ detecting of the final antibody's enzyme or traceable entity.
46. (currently amended) The ~~claim of~~ The process as claimed in claim 36, or 44, or 45 where the final antibody's traceable group is comprised ~~consists of~~, but is not limited to, biotin; wherein the biotin is subsequently detected by applying to the blot matrix ~~application of~~ avidin or streptavidin possessing a conjugated enzyme or traceable group entity. Wherein the amount of avidin or streptavidin is determined by colorimetric, luminescent or other based ~~detection~~ detecting of the avidin's or streptavidin's enzyme or traceable entity.
47. (currently amended) The ~~claim of~~ process as claimed in claim 36, or 44, or 45, or 46, where the (final) antibody's, or avidin's, or streptavidin's conjugated enzyme is comprised ~~consists of~~, but is not limited to, horseradish peroxidase.
48. (currently amended) The ~~claim of~~ process as claimed in claim 36, or 37 ~~The claim of~~ 35, where the surface internalizes the labeled material, and the procedure is performed to assess the quantity of labeled material internalized by the binding entity.

Wherein the exposure of said surface to the labeled ligand in varied conditions, followed by the same removing, separating, membrane binding, and detecting methods, can be used to measure surface or cellular labeled ligand binding and/or internalization.

49. (currently amended) The ~~claim of process as claimed in claim 36~~, Wherein the ~~amount of labeled material bound to the surface in the presence of excess unlabeled material; is compared to the amount of labeled material bound to the surface in the absence of unlabeled material; to ascertain specific labeled material bound.~~ specific binding of the labeled ligand to said surface can be determined by competitive binding with unlabeled ligand, followed by the same removing, separating, blotting, and detecting methods.
50. (currently amended) The product of claim of 36, where all of the components required to perform the analysis of the binding of a material to a surface are packaged together and sold as an assemblage, or a kit.
51. (currently amended) The product of claim of 36, where the components required to perform the analysis of the binding of a material to a surface in accordance with claim 1 are packaged separately, but sold together as a combination of products marked specifically for the purpose of accomplishing claim 1.